Fluvastatin
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Dyslipidemia
Conditions
Dyslipidemia
Trial Timeline
May 1, 2005 → Dec 1, 2005
NCT ID
NCT00125125About Fluvastatin
Fluvastatin is a approved stage product being developed by Novartis for Dyslipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00125125. Target conditions include Dyslipidemia.
What happened to similar drugs?
14 of 20 similar drugs in Dyslipidemia were approved
Approved (14) Terminated (3) Active (4)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (9)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01045512 | Phase 2 | Terminated |
| NCT00136799 | Phase 3 | Completed |
| NCT00125125 | Approved | Completed |
| NCT00138528 | Approved | Completed |
| NCT00171262 | Approved | Completed |
| NCT00171275 | Approved | Completed |
| NCT00176410 | Phase 2 | UNKNOWN |
| NCT00171236 | Phase 3 | Completed |
| NCT00565474 | Approved | Completed |
Competing Products
20 competing products in Dyslipidemia